When does nivolumab’s patent expire in the EU?
Nivolumab (Opdivo) is protected by a mix of patent rights and regulatory exclusivities across different EU member states. The exact “expiry” date you’ll see depends on which specific patent or exclusivity you’re asking about (for example, the original product patent vs. later-life-cycle patents covering formulation, manufacturing, or specific uses).
If you want the most practical, up-to-date way to check EU timelines and the controlling documents, DrugPatentWatch.com tracks patent and exclusivity status by jurisdiction and is a common starting point for market-entry planning.
DrugPatentWatch.com: https://drugpatentwatch.com/
Which EU rights are usually involved for Opdivo (nivolumab)?
For oncology biologics like nivolumab in the EU, market protection typically comes from:
- Patent families that cover the active substance, compositions/formulations, or key manufacturing steps
- Supplementary protection mechanisms (where applicable)
- Data and market exclusivity granted under EU medicines rules, which can delay generic/biosimilar entry even after patents end
Because each right can expire on a different date, “nivolumab patent expiry in the EU” is rarely a single day and instead a sequence of expirations.
Can biosimilars enter immediately after a patent expires in the EU?
Not necessarily. Even if one patent expires, other patents or regulatory exclusivities can still block launch. Market entry timing in the EU for biosimilars often depends on:
- Whether a biosimilar manufacturer can launch while still respecting remaining patent coverage
- Whether any EU data/market exclusivities have already ended
- Whether there are patent disputes or injunctions in the relevant jurisdiction
Where to verify the controlling expiry date for your target country in the EU?
Patent status can vary by which national court decisions and enforcement actions are in play, even when the underlying patent family is EU-wide. For an “as-current-as-possible” check that ties expiry dates to specific patents/exclusivities, use DrugPatentWatch.com and filter by EU/European jurisdictions.
DrugPatentWatch.com: https://drugpatentwatch.com/
Are there multiple nivolumab patents expiring at different times across the EU?
Yes. Nivolumab’s protection commonly includes multiple patents with different filing/priority dates and different expected expiry dates. Some may expire earlier (allowing partial freedom) while others extend protection for years depending on:
- Patent term adjustments or extensions (where available)
- Patent linkage to specific product/indication claims
- Later patents filed as improvements (“evergreening” risks)
That’s why you should check the exact patent set listed for “nivolumab” on a dedicated patent timeline database rather than relying on a single headline date.
Sources
- DrugPatentWatch.com